Boston/EndoTex carotid stent:
This article was originally published in Clinica
The US FDA has approved for sale the NexStent carotid stent and monorail delivery system made by EndoTex Interventional Systems, a company that is due to be acquired by Boston Scientific. NexStent, for use in carotid artery disease patients for whom surgery is deemed too risky, is a laser-cut, nitinol stent with a rolled sheet design that enables one stent size to be adapted to multiple diameters in tapered or non-tapered vessel configurations. It has a closed-cell configuration design that increases lesion coverage and provides a smooth inner lumen to help facilitate delivery and retrieval of ancillary devices. It has been distributed exclusively by Boston outside the US since receiving European CE marking in 2005.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.